Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of calycosin in medicines

A technology of mullevisoflavone and drug, applied in the field of medicine, can solve problems such as failure to clarify the mechanism of action of mullein on laryngeal cancer, inability to select drugs correctly, and the like

Inactive Publication Date: 2019-12-31
HUZHOU CENT HOSPITAL
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, this invention does not clarify the mechanism of action of calycosin on laryngeal cancer. Even though this drug works well on laryngeal cancer, it cannot be used to prepare drugs for other tumors, and the drug cannot be correctly selected according to the characteristics of the tumor and the drug.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of calycosin in medicines
  • Application of calycosin in medicines
  • Application of calycosin in medicines

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0028] In this embodiment, the drug is a tablet (100 mg per tablet), and the weight percentage of calycosin is 1%, including 1 mg of calycosin, 90 mg of starch, 5 mg of agar, and 4 mg of montmorillonite.

[0029] Preparation method: Mix calycosin with starch, agar, and montmorillonite evenly, add appropriate amount of water, and granulate the powder. After drying, sieve the granules and press into tablets.

Embodiment 2

[0031] In this embodiment, the drug is a granule, and the weight percentage of calycosin is 99%, including 99 mg of calycosin and 1 mg of alginate.

[0032] Preparation method: Mix calycosin and alginate evenly, use appropriate amount of water to make soft material, granulate, dry, granulate, and pack.

Embodiment 3

[0034] In this embodiment, the drug is a capsule, and the weight percentage of calycosin is 50%, including 50 mg of calycosin, 5 mg of lactose, 5 mg of sucrose, 10 mg of agar, 25 mg of starch, and 5 mg of kaolin.

[0035] Preparation method: Mix calycosin with lactose, sucrose, agar, starch and kaolin evenly, add appropriate amount of water to make a soft material, granulate, dry, granulate, and pack into capsules.

[0036] Explain the mechanism of action of calycosin in the medicine of the present invention by following experiment:

[0037] 1. Materials and methods

[0038] (1) Cell culture

[0039] HEK293T, U251 and U81 cells used in this experiment were purchased from the Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences (Shanghai). All cells were maintained in DMEM medium at 37°C, 5% CO 2 conditions, and at the same time, 10% fetal calf serum (FCS) and 1% antibiotics (penicillin / streptomycin) were added to DMEM.

[0040] (2) CCK-8 cell proliferati...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an application of calycosin in medicines, and particularly relates to the application of calycosin in preparation of medicines for treating glioma. The calycosin has the effectof inhibiting proliferation and invasion of glioma mother cells, can be used for preparing drugs for treating glioma, and provides a better choice for glioma patients.

Description

technical field [0001] The invention relates to the technical field of medicine, in particular to an application of calycosin in medicine. Background technique [0002] Glioma is the most common primary malignant tumor in the human central system. According to the degree of malignancy, it is divided into five grades, and about 75% of them are grade III and grade IV gliomas, which are considered high-grade gliomas. Among them, glioblastoma is a malignant glioma with an average survival of only 14.6 months after diagnosis. In addition, traditional surgery combined with radiotherapy and chemotherapy is still the main treatment, but the curative effect is poor and the prognosis is poor. Therefore, there is an urgent need for new diagnosis and treatment to improve the prognosis of this tumor. [0003] Calycosin is the main bioactive compound extracted from Astragalus membranaceus, a Chinese herb commonly used in traditional Chinese medicine. Early studies have shown that caly...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/352A61P35/00
CPCA61K31/352A61P35/00
Inventor 聂小虎周跃苏忠周
Owner HUZHOU CENT HOSPITAL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com